- Lexaria Bioscience recently announced its DehydraTECH(TM) patent for pharmaceutical applications of cannabinoids to treat certain disease conditions
- Lexaria Bioscience’s patented DehydraTECH drug delivery platform can be used to deliver nicotine, cannabinoids and many other useful substances
- The company has roughly 60 patents pending in countries around the world for its DehydraTECH drug delivery platform
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is at the forefront of the development of useful biotechnology products and has played a pivotal role in developing a way to deliver substances to the brain via non-inhalation methods through the development of a novel drug delivery platform.
The DehydraTECH drug delivery platform was developed by Lexaria Bioscience Corp. and has already received patents in both the United States and Australia, most recently for pharmaceutical applications of cannabinoids to treat certain disease conditions (http://cnw.fm/J7PrV). In addition, patents are also pending in over 40 countries around the world. The delivery method can be used in a variety of forms, including in edible foods and beverages, and the technology has several benefits and applications for the pharmaceutical industry.
This innovative technology can be used to safely deliver nicotine and a range of other substances, including cannabidiol, to the body via ingestion rather than inhalation. It has been recognized that inhalation is dangerous and associated with other medical problems. Thus, finding an alternative means for the effective and safe delivery of substances which have traditionally been inhaled is advantageous. A total of nine corporations have signed 11 definitive contracts to use Lexaria’s revolutionary DehydraTECH drug delivery platform, and its client base continues to expand exponentially.
It is clearly a benefit to find and use edible or drinkable products as a way of delivering substances to the bloodstream. It is also beneficial that the delivery system works in beverages, for individuals who may be having trouble eating solid foods. Consequently, new patent applications related to the recent innovations have been filed by Lexaria (http://cnw.fm/u3W1a).
This patented delivery system works in such a way that the required substance can be absorbed by the gastrointestinal system. This is an important development, since previous edible products containing substances such as nicotine were found to be poorly absorbed from the gut, which meant that they were not very effective for the purposes of delivering the nicotine in a safe manner. In addition, no sugar additives are needed, since this product blocks any unpleasant or bitter taste. This is a big benefit, because it means that unhealthy taste-enhancing substances do not need to be added to products to make them palatable. The DehydraTECH drug delivery platform also enables the substances to bypass first phase liver metabolism.
Lexaria’s DehydraTECH drug delivery platform has been shown to rapidly deliver nicotine and cannabidiol to the brain. In general, the ingestion of nicotine and cannabinoids in this way means that far more of the substance is absorbed than through other means of edible ingestion, which is a distinct advantage. Lexaria, through its relationship with Canada’s National Research Council (“NRC”), also continues to investigate what interactions take place at the molecular level between nicotine polacrilex formulations and DehydraTECH’s methodology in order to continually improve on DehydraTECH and expand scientific understanding of its processes.
The platform does work very well in delivering non-psychoactive cannabinoids, which have been recognized as beneficial in treating many ailments (http://cnw.fm/5SbLq). In a human clinical test, DehydraTECH achieved a 319 percent higher CBD blood concentration compared with other systems within 30 minutes of ingestion.
Cannabidiol is a helpful substance that has potential for the treatment of many medical conditions, and a quick uptake of the substance is important in people who desire rapid relief of unpleasant symptoms such as nausea and pain. The CBD acts on special receptors in the brain which causes changes in how the nervous system functions (http://cnw.fm/x71Pa).
There is scientific evidence to substantiate many of the health benefits of CBD. Besides helping to alleviate symptoms of nausea, CBD has been found to work well in patients who have seizure disorders such as Dravet syndrome and Lennox-Gastaut syndrome, which are difficult to treat by conventional means. The cannabinoid also helps with pain and even anxiety.
Inhalation may be a quicker route for getting cannabinoids and certain other substances into the brain, but it is harmful to the body, which is why this new delivery technology is preferable. Lexaria Bioscience Corp. has 16 patents granted for DehydraTECH for the safe, rapid and effective delivery of cannabidiol.
A further advantage of the platform is that several other fat-soluble substances can be delivered using the DehydraTECH drug delivery platform. For instance, the DehydraTECH delivery system can be used for the rapid delivery and gastrointestinal uptake of substances including fat-soluble vitamins, such as vitamin A and E, and non-steroidal anti-inflammatory drugs, such as acetylsalicylic acid and ibuprofen. There is also potential for the use of DehydraTECH to deliver drugs that can help with nervous system disorders such as Alzheimer’s disease. This is helpful, since the blood-brain barrier has sometimes been an obstacle for the delivery of drugs to the brain. Lexaria attributes its recent commercial success largely to its rapidly expanding body of scientific results that prove the superior capabilities of its patented technologies.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have a questions or are you interested in working with CNW? Ask Our Editor